Character Biosciences

Executive Summary

Character Biosciences is a private biotechnology company based in San Francisco, founded in 2021, dedicated to combating age-related macular degeneration (AMD), a leading cause of blindness affecting one in eight people over 50. The company's approach leverages human genetics to unravel the drivers of disease progression and discover targeted small molecule therapies. By focusing on the genetic underpinnings of AMD, Character Biosciences aims to develop treatments that address the root causes rather than just symptoms, potentially offering more effective options for the millions at risk. The company is still in early stages, with no publicly disclosed pipeline or funding details, but its mission to translate genetic insights into novel therapeutics positions it within a rapidly evolving field where precision medicine is gaining traction.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Lead Program Nomination and Preclinical Data Release50% success
• Q1 2027Key Scientific Publication or Patent Filing60% success